Table 2.

Outcomes associated with REGEN-COV treatment effectiveness

		Received REGEN-COV (n = 289)	Did not received REGEN-COV (n = 1296)	Unadjusted REGEN-COV effectiveness (95%CI)	Adjusted REGEN-COV effectiveness (95% CI)
Hospitalization due to COVID-19	Yes	15	105	36.8% (−8.0–63.2%)	56.4% (23.7–75.1%)
Severe COVID-19	Yes	10	82	46.0% (−4.2–72.0 %)	59.2% (19.9–79.2%)
Death due to COVID-19	Yes	1	27	83.3% (−23.0–97.7%)	93.5% (52.1–99.1%)

Abbreviation: CI Confidence Interval.

Note: Treatment effectiveness was measured as a 1-Hazard ratio (HR), derived from a Cox–proportional model that was applied after the matching. Patients were matched using an optimal matching scheme, including the following variables: Age, population sector, sex, SES, BMI, immunosuppression status, pregnancy, and first vaccination dose status.

The Cox model was then further adjusted for age, population sector, sex, SES, BMI, number of flu vaccines received in the five years prior to COVID-19 infection, smoking status, recent full vaccination status, first vaccination dose, and chronic diseases (cancer, chronic kidney disease, respiratory diseases, cardiovascular diseases, diabetes, hypertension, immunosuppression, neurological conditions, and liver diseases). Complete variable definitions are found in Supplemental Table 7.